DDInter1951 DDInter1658
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Warfarin {u} (Compound) resembles {v} (Compound) Benzyl Benzoate
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenytoin
Warfarin {u} (Compound) resembles {v} (Compound) Fenoprofen
Warfarin {u} (Compound) binds {v} (Gene) CYP2C8
Warfarin {u} (Compound) upregulates {v} (Gene) CDK6
Warfarin {u} (Compound) is included by {v} (Pharmacologic Class) Vitamin K Inhibitors
Warfarin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Warfarin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Albiglutide
Warfarin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mercaptopurine
Warfarin {u} may lead to a major life threatening interaction when taken with {v} Meloxicam
Warfarin (Compound) resembles Benzyl Benzoate (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin
Warfarin (Compound) resembles Fenoprofen (Compound)
Warfarin (Compound) binds CYP2C8 (Gene)
Warfarin (Compound) upregulates CDK6 (Gene)
Warfarin (Compound) is included by Vitamin K Inhibitors (Pharmacologic Class)
Warfarin may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine
Warfarin may lead to a major life threatening interaction when taken with Meloxicam